Abbott Laboratories is set to reshape its market presence with the acquisition of Exact Sciences for $23 billion, entering the lucrative $60 billion U.S. cancer screening and precision oncology market. This move aligns with Abbott's two-pronged investment strategy targeting high-growth sectors, particularly diabetes and cardiovascular health, despite a challenging backdrop of declining stock performance. The company has reported a 13% year-over-year growth in Rhythm Management sales and forecasts organic sales growth of 6.5% to 7.5% for 2026, while also seeking $100 million in annual synergies from the deal by 2028.
“Top five holdings · include · NYSE:ABT · $23.58 million (10.6% of AUM)”
“Abbott · pursues · investment strategy · two-pronged”
“Abbott · is directing resources to support · momentum in Diabetes, Structural Heart, Electrophysiology and Heart Failure · high-growth areas”
“Abbott · continues to invest to improve · growth outlook in foundational segments · Rhythm Management and Vascular”
“Abbott’s Rhythm Management sales · grew · year over year · 13%”
“Abbott · completed · patient enrollment · in its CATALYST trial”
“Abbott · demonstrated that · Libre technology helps people with Type 2 diabetes · improve glucose management”
“Abbott · is trading at · forward 12-month Price/Earnings (P/E) · 15.31X”
“Abbott · carries · Zacks Rank · #4 (Sell)”
“Abbott · is targeting · 50 to 70 basis points of annual operating margin improvement · true”
“Abbott · acquired · Exact Sciences · March 23, 2026”
“Abbott · entered · $60 billion U.S. cancer screening and precision oncology market · true”